https://pittplusme.org/study/1960
DRM-20-012 – Eczema Study
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Do you have eczema? You may be able to participate in a study to test whether an investigational study drug called lebrikizumab impacts the effectiveness of certain vaccines (meningococcal vaccines – MCV and tetanus, diphtheria, and pertussis – Tdap) and also if it is safe and if it works in people with eczema. This study involves 7-11 visits over 32 weeks. Compensation is provided.
IRB: 20203191
- A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis
AGE:
18-55
DURATION:
32 weeks
VISITS:
7-11
LOCATION:
Falk Medical Building - Oakland
COMPENSATION:
Up to $450
SHARE STUDY
MEET THE RESEARCHER
Laura Ferris
Laura Korb Ferris, MD, PhD, is Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.